PRESS RELEASE

2025.09.01

Change of Our Office Address

2025.04.29

Publication of Research Article Co-Authored with Experts in the Field of AMD

2024.04.25

NeoVascularX Licensed Exclusive Worldwide IP Rights of AMD101 Topical Ophthalmic Products from AMD Therapeutics LLC and its Co-Development Partners

2024.04.11

NeoVascularX was Incorporated in Delaware

2024.03.19

Presented AMD101 Topical Ophthalmic Products at 4th Wet AMD & Diabetic Eye Disease Drug Development Summit in Boston